Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second ...

Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the ...

The revised Annual Report is be and is hereby submitted for the typographical errors as mentioned in the covering letter annexed to the disclosure.

Vertex Energy Inc (VTNR) stock saw a modest uptick, ending the day at $0.33 which represents a slight increase of $0.01 or 3.13% from the prior close of $0.32. The stock opened at $0.33 and touched a ...

Haystack, a leading modern intranet provider, today announced its collaboration with Google Cloud to integrate Google Cloud’s ...

India's semiconductor sector, despite being home to 20-25 per cent of the global design talent, has historically lacked a ...

Jupiter Endovascular today announced the first two patients treated in a study of its Vertex pulmonary embolectomy system.